UCBUCBJF 91 EBITDA Margin % is 36.30% as of Dec. 2025, which is 33% above its 10-year median of 27.36. GuruFocus rates UCBJF with a GF Score™ of 91/100 and a GF Value™ of $262.49 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, UCB ranks better than 89.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. UCB's EBITDA for the
six
months ended in Dec. 2025 was $1,808 Mil. UCB's Revenue for the
six
months ended in Dec. 2025 was $4,981 Mil. Therefore, UCB's EBITDA margin for the quarter that ended in Dec. 2025 was 36.30%.
UCB (OTCPK:UCBJF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
UCB EBITDA Margin % Related Terms
UCB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for UCB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCBJF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, UCB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where UCB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (UCBJF) has a EBITDA Margin % of 36.30% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UCB and its competitors. This is 33% above median its historical median of 27.36. Over the past decade, UCB's EBITDA Margin % has ranged from 21.23 to 33.29. According to the industry distribution chart, UCB ranks #95 out of 944 companies in the Biotechnology industry, placing it in the top 10.1%.
Is UCB's EBITDA Margin % too high?
UCB's current EBITDA Margin % of 36.30% is 33% above median its 10-year median of 27.36. Over the past 10 years, this metric has ranged from a low of 21.23 to a high of 33.29. Based on the distribution chart, UCB ranks #95 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #95 out of 944 companies for EBITDA Margin %. This places UCB in the top 10% of its industry — outperforming the majority of peers. Historically, UCB's own EBITDA Margin % has ranged from 21.23 to 33.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on UCB and its competitors. UCB's current EBITDA Margin % is 36.30%, which is 33% above median its own 10-year median of 27.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (UCBJF) is currently considered Modestly Overvalued. The stock's GF Value™ is $262.49, compared to a current price of $296.74 — trading 13% above its estimated fair value. The current EBITDA Margin % is 36.30%, which is 33% above median its 10-year median of 27.36. UCB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For UCB (UCBJF), the current EBITDA Margin % is 36.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (UCBJF) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of $296.74 is trading 13% above its estimated GF Value™ of $262.49.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for UCBJF:
EBITDA Margin %: 36.30% (33% above median its 10-year median of 27.36)
GF Value™: $262.49 vs. price of $296.74 (13% above fair value)
No single metric tells the full story. See the UCBJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score
Get the complete analysis for UCBJF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UCBJF has been successfully added to your 
